Table 2.
Pathogen Identification
| Item | Total | IFNα1b Group | Control Group |
|---|---|---|---|
| Influenza virusa | 16 (9.94%) | 9 (11.84%) | 7 (8.24%) |
| Parainfluenza virus | 4 (2.48%) | 3 (3.95%) | 1 (1.18%) |
| Respiratory syncytial virus | 7 (4.35%) | 2 (2.63%) | 5 (5.88%) |
| Rhinovirus | 7 (4.35%) | 3 (3.95%) | 4 (4.71%) |
| Adenovirus | 7 (4.35%) | 5 (6.58%) | 2 (2.35%) |
| EB virus | 16 (9.94%) | 7 (9.21%) | 9 (10.59%) |
| Herpes virus | 14 (8.64%) | 8 (10.53%) | 6 (7.06%) |
| Coronavirus | 2 (1.24%) | 1 (1.32%) | 1 (1.18%) |
| Human metapneumovirus | 1 (0.62%) | 0 (0.00%) | 1 (1.18%) |
| Streptococcus pneumoniae | 2 (1.24%) | 2 (2.63%) | 0 (0.00%) |
| Mycoplasma | 10 (6.21%) | 4 (5.26%) | 6 (7.06%) |
| Chlamydia | 2 (1.24%) | 1 (1.32%) | 1 (1.18%) |
| Moraxella catarrhalis | 2 (1.24%) | 0 (0.00%) | 2 (2.35%) |
| Simple virus infection | 49 (30.43%) | 21 (27.63%) | 28 (32.94%) |
| Single virus infection | 30 (18.63%) | 9 (11.84%) | 21 (24.71%) |
| Two-virus infection | 9 (5.59%) | 7 (9.21%) | 2 (2.35%) |
| Multivirus infection | 10 (6.21%) | 5 (6.58%) | 5 (5.88%) |
| Mycoplasma + virus | 5 (3.11%) | 2 (2.63%) | 3 (3.53%) |
| Chlamydia + virus | 2 (1.24%) | 1 (1.32%) | 1 (1.18%) |
arepresents negative results from a rapid influenza antigen test during screening and positive results from an influenza virus nucleic acid test at the central laboratory. No anti-influenza drugs were given during clinical treatment.